Place of lisinopril in the therapy of cardio-vascular complications in patients with metabolic syndrome
Metabolic syndrome (MS) is characterized by a high risk of cardiovascular complications development. One of the well-studied drugs in the ACE inhibitors group - lisinopril - can be considered as a priority in the treatment of cardiovascular complications in patients with MS. The grounds are special pharmacokinetic properties of lisinopril, its impact on the pathogenetic mechanisms of cardiovascular disease in MS and the extensive evidence base. The numerous clinical studies results show lisinopril-indused death risk reduction in patients with myocardial infarction and heart failure. Lisinopril prevents the development of diabetes, it has a cardio-and nephroprotektive actions, and effective in myocardial hypertrophy and nephropathy.

Keywords: angiotensin converting enzyme, lisinopril, metabolic syndrome, cardiovascular disease, hypertension